Nova Leap Health (NLH) Q3 2026 earnings summary

Executive summary

• Q3 revenue reached a record $9.53M, up 15.3% YoY, including 8.2% organic growth; Adjusted EBITDA rose 28.3% to $860,804.

• TTM revenue of $34.86M and Adjusted EBITDA of $2.79M were both records; Q3 operating income increased while net income declined YoY.

Financial highlights

• Q3 2026 revenue was $9,531,140 vs. $8,264,326 in Q3 2025; organic revenue growth was 8.2% YoY.

• TTM revenue for the 12 months ended Sept. 30, 2026 was $34,864,119, the highest on record.

• Q3 Adjusted EBITDA was $860,804 vs. $670,706 a year earlier; TTM Adjusted EBITDA reached a record $2,785,448.

• Q3 income from operating activities rose 54.2% to $645,562; net income was $333,771 vs. $426,171 in Q3 2025.

Outlook and guidance

• First nine months of 2026 Adjusted EBITDA exceeded the full-year 2025 result by 11.3%.

• Growth priorities include investing in existing agencies, opening new locations and pursuing acquisitions at disciplined valuations; management expects M&A to remain part of capital allocation.

• Care management and palliative care have launched, with private nursing planned; these services aim to broaden care offerings and support long-term organic growth.